Understanding how breast cancer patients use risk information from genomic tests

[1]  Gary G. Koch,et al.  Categorical data analysis using the SAS , 2012 .

[2]  M. Broder,et al.  Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. , 2011, Journal of oncology practice.

[3]  Noel T Brewer,et al.  Knowledge of genomic testing among early‐stage breast cancer patients , 2011, Psycho-oncology.

[4]  L. Carey,et al.  Women's experiences with genomic testing for breast cancer recurrence risk , 2010, Cancer.

[5]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Hayes,et al.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[8]  Lajos Pusztai,et al.  Gene expression profiling of breast cancer , 2009, Breast Cancer Research.

[9]  B. Rimer,et al.  When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapy , 2009, Breast Cancer Research and Treatment.

[10]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sarah E Lillie,et al.  Women's interest in gene expression analysis for breast cancer recurrence risk. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Noel T Brewer,et al.  Risk compensation and vaccination: Can getting vaccinated cause people to engage in risky behaviors? , 2007, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[14]  A. Cohn,et al.  Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. , 2007, Journal of oncology practice.

[15]  S. Paik.  Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.

[16]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Shak,et al.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.

[18]  F. Monzon.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[19]  S. Domchek,et al.  Patients' resistance to risk information in genetic counseling for BRCA1/2. , 2005, Archives of internal medicine.

[20]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[22]  Francis S. Collins,et al.  Genomic medicine--a primer. , 2002, The New England journal of medicine.

[23]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[24]  R. Croyle,et al.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. , 2000, Preventive medicine.

[25]  Gary G. Koch,et al.  Categorical data analysis using the sas® system, 2nd edition , 2000 .

[26]  Lisa M. Schwartz,et al.  The Role of Numeracy in Understanding the Benefit of Screening Mammography , 1997, Annals of Internal Medicine.

[27]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[28]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.